Humedics, a Berlin, Germany-based specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, closed a €6.3m Series C financing round.
The round was led by new investors Vesalius Biocapital Partners and Seventure Partners with participation from previous investors Peppermint VenturePartners (managing the Charité Biomedical Fund), VC Fonds Technologie managed by IBB-Beteiligungsgesellschaft, ERP Startfonds of the Kreditanstalt für Wiederaufbau (KfW), Ventegis and High-Tech Gründerfonds. Vesalius Managing Partner Dr. Christian Schneider and Dr. Robert Schier from Seventure Partners will join the board.
The company intends to use the funds for the European market entry of the LiMAx test and the corresponding FLIP diagnostic device.
Led by Erwin de Buijzer, Managing Director, Humedics GmbH has developed a breath test based diagnostic system (LiMAx test), which comprises a CE-marked medical device, breath masks and a diagnostic drug, which enables clinicians to quantitatively determine the individual liver function capacity for a patient within minutes. This allows for selection of treatment strategies that are optimally adapted to the individual patients liver status.
Current applications include diagnosis of the liver function before and after liver transplantation, liver surgery planning (e.g. assessment of the amount of liver to be resected without potentially increasing the risk of liver failure) and assessment of diseases such as liver cirrhosis.